MetaVia Inc. (MTVA)Healthcare | Biotechnology | Cambridge, United States | NasdaqCM
1.36 USD
-0.07
(-4.895%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 1.37 +0.01 (0.735%) ⇧ (Oct. 14, 2026, 5:59 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 11:27 a.m. EDT
The immediate outlook is severely clouded by a relentless multi-year price collapse and deteriorating fundamentals. While recent headlines celebrate a 45% spike driven by a medical conference catalyst, the underlying reality is stark: the stock has lost nearly 100% of its value over the last nine years, with every single annual period showing negative returns. This is not a temporary dip; it is a structural implosion where the market has consistently rejected the business model for a decade. The company is burning through cash, reporting significant losses, and carrying negative returns on both assets and equity. The recent rally appears to be a classic 'dead cat bounce' fueled by speculative hype rather than a reversal of the long-term trend. With no analyst coverage, a massive gap between the current price and the mean target price that ignores the fundamental rot, and a balance sheet that offers no safety net, the risk-reward profile is overwhelmingly negative. Investors chasing the latest news are likely buying the top of a long-term decline. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.076250 |
| MSTL | 0.078427 |
| AutoTheta | 0.215597 |
| AutoARIMA | 0.413705 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 21.78 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.153 |
| Excess Kurtosis | -1.35 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.595 |
| Market Cap | 8,959,817 |
| Beta | 0.96 |
| Previous Name | NeuroBo Pharmaceuticals, Inc. |
| Website | https://www.metaviatx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.875 |
| Address1 | 545 Concord Avenue |
| Address2 | Suite 210 |
| All Time High | 1,424,940.0 |
| All Time Low | 0.966 |
| Ask | 1.98 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 70,710 |
| Average Daily Volume3 Month | 83,858 |
| Average Volume | 83,858 |
| Average Volume10Days | 70,710 |
| Beta | 0.957 |
| Bid | 1.12 |
| Bid Size | 2 |
| Book Value | 1.037 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.36 |
| Current Ratio | 2.059 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.4354 |
| Day Low | 1.3504 |
| Debt To Equity | 2.595 |
| Display Name | MetaVia |
| Dividend Date | 1,577,750,400 |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,755,520,200 |
| Earnings Timestamp Start | 1,755,001,800 |
| Ebitda | -14,912,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.235 |
| Enterprise Value | -3,499,182 |
| Eps Trailing Twelve Months | -3.55 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.5766 |
| Fifty Day Average Change | -0.21659994 |
| Fifty Day Average Change Percent | -0.1373842 |
| Fifty Two Week Change Percent | -87.5 |
| Fifty Two Week High | 14.85 |
| Fifty Two Week High Change | -13.490001 |
| Fifty Two Week High Change Percent | -0.9084175 |
| Fifty Two Week Low | 0.966 |
| Fifty Two Week Low Change | 0.394 |
| Fifty Two Week Low Change Percent | 0.4078675 |
| Fifty Two Week Range | 0.966 - 14.85 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,470,403,800,000 |
| Float Shares | 4,804,307 |
| Free Cashflow | -11,086,875 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 8 |
| Fullday Change | -0.059999943 |
| Fullday Change Percent | -4.1958003 |
| Fullday Price | 1.36 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.2861 |
| Held Percent Institutions | 0.13866 |
| Implied Shares Outstanding | 6,588,101 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,764,892,800 |
| Last Split Factor | 1:11 |
| Long Business Summary | MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts. |
| Long Name | MetaVia Inc. |
| Market | us_market |
| Market Cap | 8,959,817 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_630763379 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-15 |
| Net Income To Common | -14,446,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,771,545 |
| Number Of Analyst Opinions | 3 |
| Open | 1.4354 |
| Operating Cashflow | -15,835,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 857 702 9600 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.7352934 |
| Post Market Price | 1.37 |
| Post Market Time | 1,792,015,173 |
| Prev Name | NeuroBo Pharmaceuticals, Inc. |
| Previous Close | 1.43 |
| Price Hint | 4 |
| Price To Book | 1.3114755 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.991 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0699999 |
| Regular Market Change Percent | -4.8951 |
| Regular Market Day High | 1.4354 |
| Regular Market Day Low | 1.3504 |
| Regular Market Day Range | 1.3504 - 1.4354 |
| Regular Market Open | 1.4354 |
| Regular Market Previous Close | 1.43 |
| Regular Market Price | 1.36 |
| Regular Market Time | 1,792,008,000 |
| Regular Market Volume | 40,615 |
| Return On Assets | -0.58821 |
| Return On Equity | -1.7567799 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 6,588,101 |
| Shares Percent Shares Out | 0.0178 |
| Shares Short | 117,409 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 210,868 |
| Short Name | MetaVia Inc. |
| Short Percent Of Float | 0.024400001 |
| Short Ratio | 1.36 |
| Source Interval | 15 |
| State | MA |
| Symbol | MTVA |
| Target High Price | 30.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 19.33333 |
| Target Median Price | 20.0 |
| Total Cash | 12,636,000 |
| Total Cash Per Share | 1.918 |
| Total Debt | 177,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.55 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.136025 |
| Two Hundred Day Average Change | -0.77602494 |
| Two Hundred Day Average Change Percent | -0.3633033 |
| Type Disp | Equity |
| Volume | 40,615 |
| Website | https://www.metaviatx.com |
| Zip | 2,138 |